Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients

Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients Prostate Cancer and Prostatic Diseases advance online publication, August 13 2013. doi:10.1038/pcan.2013.26 Authors: J Z Cerne, S E McGuire, S R Grant, M F Munsell, A K Lee, R J Kudchadker, S L Choi, U Mahmood, K E Hoffman, T J Pugh, S J Frank &D A Kuban
Source: Prostate Cancer and Prostatic Diseases - Category: Urology & Nephrology Authors: Tags: neoadjuvant androgen deprivation therapy radiation therapy biochemical response high-risk intermediate-risk Source Type: research

Related Links:

iot S, Pasquier D Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80% of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial prostate specific antigen serum concentration value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controvers...
Source: Cancer Radiotherapie - Category: Cancer & Oncology Authors: Tags: Cancer Radiother Source Type: research
RARITAN, N.J., February 3, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today multiple data presentations from a robust solid tumor portfolio that will be featured at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15 in San Francisco. Company-sponsored data presentations will include clinical results for ERLEADA® (apalutamide) and niraparib in prostate cancer; and BALVERSA™ (erdafitinib) in bladder cancer. “We are committed to improving outcomes in patients with prostate and bladder cancer where high unmet ...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
ConclusionIMRT at a dose up to 78  Gy combined with short-term neoadjuvant ADT resulted in excellent long-term disease-free outcomes with acceptable morbidities among patients with IR PCa. In addition, the incidence of late recurrence was very low. Further investigation is warranted to confirm our findings.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Purpose of review Local treatment of the primary by either radical prostatectomy or radiation therapy is discussed controversially. The role of cytoreductive radical prostatectomy has been evaluated in few retrospective clinical studies but data of prospective randomized clinical phase-III trials are lacking. It is the purpose of this review to reflect the current knowledge on indication, functional and oncological outcomes of cytoreductive radical prostatectomy to objectively highlight what can be expected from this approach. Recent findings Cytoreductive radical prostatectomy (cRP) is associated with a long overall ...
Source: Current Opinion in Urology - Category: Urology & Nephrology Tags: SPECIAL COMMENTARIES Source Type: research
ConclusionUndifferentiated pleomorphic sarcoma should be a differential in subcutaneous lesions in older adults with a previous history of malignancy, radiation therapy and a mass in the subcutaneous tissue of the back.
Source: International Journal of Surgery Case Reports - Category: Surgery Source Type: research
Abstract BACKGROUND AND PURPOSE: To identify early biochemical predictors of survival in intermediate- and high-risk prostate cancer patients with a pre-treatment PSA
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
This study evaluated the efficacy of early initiation of salvage-ADT (S-ADT) based on predetermined timing among patients with unfavorable PCa treated with high-dose intensity-modulated radiation therapy (IMRT).Materials and methodsHigh-risk (HR) and very-high-risk (VHR) PCa patients treated with IMRT at our institution between September 2000 and December 2010 were analyzed retrospectively. Treatment consisted of high-dose IMRT (78  Gy/39 fractions) combined with 6 months of neoadjuvant-ADT (NA-ADT). S-ADT was initiated when prostate-specific antigen levels exceeded 4.0 ng/mL.ResultsIn total, 268 (184  ...
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Neoadjuvant hormone therapy (NHT) when given to men receiving radiation therapy (RT) for prostate cancer is known to affect long term testosterone (T) levels. Men with suppressed T may experience a lower PSA value which could influence biochemical failure determinations. We sought to determine which factors influenced the last measured T and PSA values and the relationship between the two.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Conclusion: Fat fraction on MRI corresponded to fat content on histology and therefore contributes to lesion characterization. Measurement repeatability was excellent for ADC; this parameter increased significantly post-radiotherapy even in disease categorized as stable by size criteria, and corresponded to cellularity on histology. ADC can be utilized for characterizing and assessing response in heterogeneous retroperitoneal sarcomas. Introduction Soft-tissue sarcomas are often highly heterogeneous tumors with variable components that can include cellular tumor, fat, necrosis, and cystic change. In many soft-tissue ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSION: Serum PSA level of 0.2 ng/mL as the definition for biochemical recurrence after RP may delay salvage treatment. Our results showed that cut off value of ?0.1 ng/mL may be more precise in the era of early salvage treatment. PMID: 31004342 [PubMed - as supplied by publisher]
Source: Urology Journal - Category: Urology & Nephrology Authors: Tags: Urol J Source Type: research
More News: Cancer | Cancer & Oncology | Grants | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Prostate Cancer | Radiation Therapy | Urology & Nephrology